Paris, France – February 10, 2021

ENTEROME SA, a clinical-stage biopharmaceutical company focused on the discovery and development of novel microbiome driven therapeutics based on the unrivalled understanding of the gut microbiome’s interaction with the human immune system, today announced that the company’s management will participate in the upcoming (virtual) investor events:

• Chardan Virtual Microbiome Medicines Summit: March 8
• H.C. Wainwright Global Life Sciences Conference: March 9-10

Pierre Belichard, Enterome’s CEO, will present the Company and take part in 1-on-1 meetings with institutional investors.

Mr Belichard will also take part in a panel discussion on the Microbiome & Cancer at:

• USF Microbiome Virtual Corporate Forum Series, a free-to-register event (click here), on March 10 from 10:00-12:00 EST.

---

Download the press release (.pdf format)